Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

96.34EUR
7:21am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€96.34
Open
€95.50
Day's High
€96.36
Day's Low
€95.48
Volume
92,594
Avg. Vol
456,813
52-wk High
€105.35
52-wk Low
€70.64

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

Beta: 1.23
Market Cap(Mil.): €5,231.18
Shares Outstanding(Mil.): 54.30
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -2.46 -- --
ROI: -11.43 1.50 12.72
ROE: -12.84 0.19 14.85

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Galapagos shares soar on $4-6 billion hopes for new drug

LONDON Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

Galapagos shares soar on $4-6 bln hopes for new drug

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Sep 12 2018

BRIEF-Galapagos NV reports H1 Group Revenues Of €101.9 Million

* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION

Aug 02 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Jul 19 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Jul 19 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

Jun 21 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

May 01 2018

BRIEF-Galapagos Presents Strong Disease-Modifying Effects With Glpg1972 At Oarsi 2018

* REG-GALAPAGOS PRESENTS STRONG DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODEL OF OSTEOARTHRITIS WITH GLPG1972 AT OARSI 2018

Apr 27 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

Apr 25 2018

Earnings vs. Estimates